Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MyoRx is a topical cream formulation containing 6% omega-3 fatty acids, specifically developed for the treatment of myofascial pain syndrome, particularly in patients with temporomandibular disorders (TMD). Developed by researchers at the University of Washington and associated with MyoRx, Inc., the cream is designed for application to the muscles of mastication. Its mechanism of action leverages the anti-inflammatory properties of polyunsaturated omega-3 fatty acids, which work to lower the levels of proinflammatory cytokines at the site of application. This topical delivery system was developed as a localized alternative to systemic omega-3 supplementation, aiming to achieve therapeutic efficacy with minimal side effects and no substantial morbidity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MyoRx.